{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:54:15Z","timestamp":1787032455256,"version":"build-2736575974"},"reference-count":41,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>Depressive episodes are more challenging for patients and clinicians than other bipolar disorder episodes. The reasons for this include: 1. the prevalence of depressive episodes is higher than for other episodes; 2. functioning; 3. cognition is more impaired; 4. suicide is more prevalent; 5. and treatment is more complex. This paper aims to highlight the controversy between the poor evidence from science on the effects of antidepressants for bipolar depression versus the high use of antidepressants in clinical practice, and to specify the clinical role of antidepressants in bipolar disorder in relation to other drugs.<\/jats:p>","DOI":"10.61409\/a07250539","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:54:31Z","timestamp":1764237271000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["The use of antidepressants for bipolar disorder - a controversy between science and clinical practice"],"prefix":"10.61409","author":[{"given":"Lars Vedel","family":"Kessing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40208","published-online":{"date-parts":[[2025,11]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537. https:\/\/doi.org\/10.1001\/archpsyc.59.6.530","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269. https:\/\/doi.org\/10.1001\/archpsyc.60.3.261","DOI":"10.1001\/archpsyc.60.3.261"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rosa AR, Reinares M, Franco C, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord. 2009 Jun;11(4):401-9. https:\/\/doi.org\/10.1111\/j.1399-5618.2009.00698.x","DOI":"10.1111\/j.1399-5618.2009.00698.x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Burdick KE, Millett CE, Yocum AK, et al. Predictors of Functional Impairment in Bipolar Disorder: Results From 13 Cohorts From Seven Countries by the Global Bipolar Cohort Collaborative. Focus (Am Psychiatr Publ). 2023;21(4):444-452. https:\/\/doi.org\/10.1176\/appi.focus.23021021","DOI":"10.1176\/appi.focus.23021021"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Demant KM, Vinberg M, Kessing LV, Miskowiak KW. Assessment of subjective and objective cognitive function in bipolar disorder: correlations, predictors and the relation to psychosocial function. Psychiatry Res. 2015;229:565-571. https:\/\/doi.org\/10.1016\/j.psychres.2015.05.022","DOI":"10.1016\/j.psychres.2015.05.022"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Marangell LB, Bauer MS, Dennehy EB, et al. Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord. 2006;8(5 Pt 2):566-575. https:\/\/doi.org\/10.1111\/j.1399-5618.2006.00369.x","DOI":"10.1111\/j.1399-5618.2006.00369.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Yildiz A, Siafis S, Mavridis D, Vieta E, Leucht S. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2023;10:693-705. https:\/\/doi.org\/10.1016\/S2215-0366(23)00199-2","DOI":"10.1016\/S2215-0366(23)00199-2"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12:87-94. https:\/\/doi.org\/10.1111\/j.1399-5618.2009.00788.x","DOI":"10.1111\/j.1399-5618.2009.00788.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord. 2016;18:174-182. https:\/\/doi.org\/10.1111\/bdi.12371","DOI":"10.1111\/bdi.12371"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression: data from the European drug surveillance program AMSP. BMC Psychiatry. 2012;12:153. https:\/\/doi.org\/10.1186\/1471-244X-12-153","DOI":"10.1186\/1471-244X-12-153"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Singh B, Yocum AK, Strawbridge R, et al. Patterns of pharmacotherapy for bipolar disorder: A GBC survey. Bipolar Disord. 2024;26(1):22-32. https:\/\/doi.org\/10.1111\/bdi.13366","DOI":"10.1111\/bdi.13366"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. https:\/\/doi.org\/10.1111\/bdi.12609","DOI":"10.1111\/bdi.12609"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ghaemi SN, Whitham EA, Vohringer PA, et al. Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry. 2021;82(1):19m13136. https:\/\/doi.org\/10.4088\/JCP.19m13136","DOI":"10.4088\/JCP.19m13136"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"McGirr A, V\u00f6hringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138-1146. https:\/\/doi.org\/10.1016\/S2215-0366(16)30264-4","DOI":"10.1016\/S2215-0366(16)30264-4"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Shafiee A, Moltazemi H, Amini MJ, et al. Adjunctive antidepressants for the treatment of bipolar depression: An updated meta-analysis of randomized clinical trials. Asian J Psychiatr. 2024;91:103839. https:\/\/doi.org\/10.1016\/j.ajp.2023.103839","DOI":"10.1016\/j.ajp.2023.103839"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Liu B, Zhang Y, Fang H, Liu J, Liu T, Li L. Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials. J Affect Disord. 2017;223:41-48. https:\/\/doi.org\/10.1016\/j.jad.2017.07.023","DOI":"10.1016\/j.jad.2017.07.023"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Yatham LN, Arumugham SS, Kesavan M, et al. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. N Engl J Med. 2023;389(5):430-440. https:\/\/doi.org\/10.1056\/NEJMoa2300184","DOI":"10.1056\/NEJMoa2300184"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Haenen N, Kamperman AM, Prodan A, Nolen WA, Boks MP, Wesseloo R. The efficacy of lamotrigine in bipolar disorder: A systematic review and meta-analysis. Bipolar Disord. 2024;26(5):431-441.https:\/\/doi.org\/10.1111\/bdi.13452","DOI":"10.1111\/bdi.13452"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13-20. https:\/\/doi.org\/10.1097\/jcp.0b013e3181618eb4","DOI":"10.1097\/jcp.0b013e3181618eb4"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1413-1422. https:\/\/doi.org\/10.4088\/JCP.09m05934","DOI":"10.4088\/JCP.09m05934"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 2012;32:470-478. https:\/\/doi.org\/10.1097\/JCP.0b013e31825ccde5","DOI":"10.1097\/JCP.0b013e31825ccde5"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121:404-414. https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01514.x","DOI":"10.1111\/j.1600-0447.2009.01514.x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Oliva V, De Prisco M, La Spina E, et al. Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials. EClinicalMedicine. 2025;87:103413. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103413","DOI":"10.1016\/j.eclinm.2025.103413"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Rodrigues Cordeiro C, C\u00f4rte-Real BR, Saraiva R, Frey BN, Kapczinski F, de Azevedo Cardoso T. Triggers for acute mood episodes in bipolar disorder: A systematic review. J Psychiatr Res. 2023;161:237-260. https:\/\/doi.org\/10.1016\/j.jpsychires.2023.03.008","DOI":"10.1016\/j.jpsychires.2023.03.008"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009;166(2):164-172. https:\/\/doi.org\/10.1176\/appi.ajp.2008.08030322","DOI":"10.1176\/appi.ajp.2008.08030322"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124-131. https:\/\/doi.org\/10.1192\/bjp.bp.105.013045","DOI":"10.1192\/bjp.bp.105.013045"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6(1):25. https:\/\/doi.org\/10.1186\/s40345-018-0133-9","DOI":"10.1186\/s40345-018-0133-9"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166(2):173-181. https:\/\/doi.org\/10.1176\/appi.ajp.2008.08050746","DOI":"10.1176\/appi.ajp.2008.08050746"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171(10):1067-1073. https:\/\/doi.org\/10.1176\/appi.ajp.2014.13111501","DOI":"10.1176\/appi.ajp.2014.13111501"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Rohde C, \u00d8stergaard SD, Jefsen OH. A Nationwide Target Trial Emulation Assessing the Risk of Antidepressant-Induced Mania Among Patients With Bipolar Depression. Am J Psychiatry. 2024;181(7):630-638. https:\/\/doi.org\/10.1176\/appi.ajp.20230477","DOI":"10.1176\/appi.ajp.20230477"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Pavlova B, Perlis RH, Alda M, Uher R. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2(8):710-717. https:\/\/doi.org\/10.1016\/S2215-0366(15)00112-1","DOI":"10.1016\/S2215-0366(15)00112-1"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Vieta E, Valent\u00ed M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27:515-529. https:\/\/doi.org\/10.1007\/s40263-013-0073-y","DOI":"10.1007\/s40263-013-0073-y"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Medda P, Perugi G, Zanello S, Ciuffa M, Cassano GB. Response to ECT in bipolar I, bipolar II and unipolar depression. J Affect Disord. 2009;118(1-3):55-59. https:\/\/doi.org\/10.1016\/j.jad.2009.01.014","DOI":"10.1016\/j.jad.2009.01.014"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Popiolek K, Bejerot S, Brus O, et al. Electroconvulsive therapy in bipolar depression - effectiveness and prognostic factors. Acta Psychiatr Scand. 2019;140(3):196-204. https:\/\/doi.org\/10.1111\/acps.13075","DOI":"10.1111\/acps.13075"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Kessing LV. Why is lithium [not] the drug of choice for bipolar disorder? a controversy between science and clinical practice. Int J Bipolar Disord. 2024;12(1):3.https:\/\/doi.org\/10.1186\/s40345-023-00322-7","DOI":"10.1186\/s40345-023-00322-7"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Ketter TA. Definition of the term \"mood stabilizer\". Bipolar Disord. 2018;20(1):74-75. https:\/\/doi.org\/10.1111\/bdi.12579","DOI":"10.1111\/bdi.12579"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Malhi GS, Chengappa KNR. Why 'mood stabilizer' needs stability: Polar views on its utility. Bipolar Disord. 2017;19(6):414-416. https:\/\/doi.org\/10.1111\/bdi.12562","DOI":"10.1111\/bdi.12562"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Malhi GS, Bauer M. Lithium first: Not merely first line. Bipolar Disord. 2023;25(1):7-8. https:\/\/doi.org\/10.1111\/bdi.13299","DOI":"10.1111\/bdi.13299"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351-359. https:\/\/doi.org\/10.1016\/S2215-0366(14)70314-1","DOI":"10.1016\/S2215-0366(14)70314-1"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Nestsiarovich A, Gaudiot CES, Baldessarini RJ, Vieta E, Zhu Y, Tohen M. Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2022;54:75-89. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.08.264","DOI":"10.1016\/j.euroneuro.2021.08.264"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Ulrichsen A, Hamosey E, Taylor RH, Gadelrab R, Strawbridge R, Young AH. Comparing measurements of lithium treatment efficacy in people with bipolar disorder: systematic review and meta-analysis. BJPsych Open. 2023;9:e98. https:\/\/doi.org\/10.1192\/bjo.2023.64 (Correction : https:\/\/doi.org\/10.1192\/bjo.2024.807)","DOI":"10.1192\/bjo.2024.807"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:26:09Z","timestamp":1765376769000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A07250539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":41,"URL":"https:\/\/doi.org\/10.61409\/a07250539","relation":{},"ISSN":["2245-1919"],"issn-type":[{"value":"2245-1919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}